TORONTO, Feb. 4 /CNW/ - Biosign Technologies Inc. (TSX-V: BIO; "Biosign"), a company focused on non-invasive monitoring of common health risks
associated with blood pressure, glucose and medication, announced today
that it will be presenting at the 2nd Annual Burrill Digital Health
Meeting being held at the San Francisco Airport Marriott from February
23-24, 2011. Mr. Peter Tassiopoulos, Biosign's CEO, will present during
a panel discussion entitled "Wellness Technology Innovations", on
February 24, 2011 from 1:30pm - 2:30pm PT.
The Burrill Digital Health Meeting showcases the underlying issues,
emerging business opportunities and cutting-edge innovations for
healthcare practices and products based on mobile and wireless
technologies. This conference provides Biosign with an ideal platform
to describe its technology, increase brand awareness, and build
strategic relationships for its ISO-certified and CE-marked UFIT®
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for non-invasive monitoring of
common health risks associated with blood pressure, glucose and
medication. The core technology combines measurement, analysis and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com.
About Burrill & Company
Burrill & Company is a life sciences merchant bank focused exclusively
on companies involved in biotechnology, pharmaceuticals, diagnostics,
devices, human healthcare and related medical technologies,
nutraceuticals and wellness, agricultural biotechnology, and industrial
biotechnology (biomaterials/bioprocesses) with over $950 million under
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
"Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release."
SOURCE Biosign Technologies Inc.
For further information:
|Peter Tassiopoulos, CEO |
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
| || || || || || || || || || ||Alan Roemer|
The Trout Group
Phone: 646 378-2945